NCT07506902 A Study of Adaptive Radiotherapy of Head-neck Cancer Using Daily Replanning and Optimization of the Treatment Plan.
| NCT ID | NCT07506902 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Rigshospitalet, Denmark |
| Condition | Head & Neck Squamous Cell Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2023-11-21 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2023-11-21 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Radiotherapy of head-neck cancer is associated with significant side effects. Using daily online adaptive radiotherapy to account for the changing anatomy, radiation to organs at risk can be lowered. We will investigate whether this is feasible and associated with a reduction in the risk of toxicity.
Eligibility Criteria
Inclusion Criteria: * Patients with histologically proven squamous cell carcinoma of the pharynx or larynx planned for primary radiotherapy with curative intent No current or earlier malignancies, which may influence treatment, evaluation or outcome of the head-neck cancer Informed consent as required by law The patient cannot participate in conflicting protocols Stage I-IV (excluding T1-T2N0 carcinoma of the glottic larynx) ECOG/WHO performance status 0-2 Exclusion Criteria: Patient with cancers of the glottic larynx (stage I/II), skull base, sino-nasal area and unknown primary tumor. Inability to attend full course of radiotherapy or follow-up visits in the outpatient clinic Distant metastasis Previous radiotherapy of the head and neck Previous surgery for the primary cancer with curative intent \-
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07506902 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Head & Neck Squamous Cell Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07506902 currently recruiting?
Yes, NCT07506902 is actively recruiting participants. Contact the research team at jeppe.friborg@regionh.dk for enrollment information.
Where is the NCT07506902 trial being conducted?
This trial is being conducted at Copenhagen, Denmark.
Who is sponsoring the NCT07506902 clinical trial?
NCT07506902 is sponsored by Rigshospitalet, Denmark. The trial plans to enroll 40 participants.